Trials / Conditions / Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

13 registered clinical trials studyying Locally Advanced or Metastatic Non-Small Cell Lung Cancer — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	A Phase II Study of QL1706 and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advance NCT07200947	Zhijie Wang	Phase 2
Recruiting	Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Ca NCT07175220	Jiangsu HengRui Medicine Co., Ltd.	Phase 2
Recruiting	A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AST2303 Tablets (ABK3376 Table NCT06955988	Allist Pharmaceuticals, Inc.	Phase 1
Unknown	A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC NCT05863325	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Phase 2
Unknown	Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer NCT05673590	Beijing Biostar Pharmaceuticals Co., Ltd.	Phase 3
Unknown	Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer NCT05513664	Shanghai JMT-Bio Inc.	—
Recruiting	A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid NCT04996121	Xuanzhu Biopharmaceutical Co., Ltd.	Phase 1 / Phase 2
Unknown	Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer NCT05132777	Shanghai JMT-Bio Inc.	Phase 2
Active Not Recruiting	A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unr NCT05048797	AstraZeneca	Phase 3
Recruiting	Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Me NCT04686305	AstraZeneca	Phase 1
Recruiting	Study of PF-07248144 in Advanced or Metastatic Solid Tumors NCT04606446	Pfizer	Phase 2
Unknown	Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Can NCT04448379	Shanghai JMT-Bio Inc.	Phase 1
Terminated	Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant NCT01526928	Clovis Oncology, Inc.	Phase 1 / Phase 2